Last reviewed · How we verify

EPOGAM 1000

Max Zeller Soehne AG · FDA-approved active Small molecule ✓ Verified May 2026 Quality 5/100

EPOGAM 1000 is a Small molecule drug developed by Max Zeller Soehne AG. It is currently FDA-approved. Also known as: Oenothera seminis oleum, Evening Primrose Oil, EPOGAM.

EPOGAM 1000 is a small molecule intervention used in a study to investigate its effects on inflammatory markers. The study, titled "The Effects of Oral Supplementation With Bend Beauty's Anti-Aging Formula on Inflammatory Markers," is focused on conditions such as inflammation, skin abnormalities, and skin pigmentation.

At a glance

Generic nameEPOGAM 1000
Also known asOenothera seminis oleum, Evening Primrose Oil, EPOGAM
SponsorMax Zeller Soehne AG
ModalitySmall molecule
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about EPOGAM 1000

What is EPOGAM 1000?

EPOGAM 1000 is a Small molecule drug developed by Max Zeller Soehne AG.

Who makes EPOGAM 1000?

EPOGAM 1000 is developed and marketed by Max Zeller Soehne AG (see full Max Zeller Soehne AG pipeline at /company/max-zeller-soehne-ag).

Is EPOGAM 1000 also known as anything else?

EPOGAM 1000 is also known as Oenothera seminis oleum, Evening Primrose Oil, EPOGAM.

What development phase is EPOGAM 1000 in?

EPOGAM 1000 is FDA-approved (marketed).

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing